NORMINEST FE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORMINEST FE (NORMINEST FE).
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
| Metabolism | Norethindrone acetate: extensively metabolized in the liver via reduction and conjugation. Active metabolite: norethindrone. Ethinyl estradiol: metabolized via CYP3A4 and conjugation (glucuronidation and sulfation). Undergoes enterohepatic recirculation. |
| Excretion | Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%. |
| Half-life | Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days. |
| Protein binding | Norethindrone: 61% bound to albumin, 36% to SHBG; ethinyl estradiol: 98% bound to albumin. |
| Volume of Distribution | Norethindrone: 3.6 ± 0.7 L/kg; ethinyl estradiol: 1.8 ± 0.5 L/kg. Reflects distribution to tissues. |
| Bioavailability | Norethindrone: 64% (oral); ethinyl estradiol: 48% (oral) due to first-pass metabolism. |
| Onset of Action | Oral: contraceptive effect requires 7 days of consistent use; menstrual regulation within 7-10 days. |
| Duration of Action | Oral: 24-hour dosing interval; withdrawal bleeding typically occurs 2-3 days after last active pill. |
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate impairment; contraindicated in severe renal impairment or acute renal failure due to potential fluid retention. |
| Liver impairment | Contraindicated in Child-Pugh class B or C; use with caution in Child-Pugh class A; monitor liver function. |
| Pediatric use | Not indicated for use before menarche; for adolescents, same dosing as adults after menarche; safety and efficacy established in females of reproductive age. |
| Geriatric use | Not indicated for use in postmenopausal women; no dosing studies in geriatric population; use not recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORMINEST FE (NORMINEST FE).
| Breastfeeding | NORMINEST FE reduces milk production and quality. Estrogen and progestin are excreted in breast milk. M/P ratio unreported. Use only if benefit outweighs risk; poorest choice for lactation suppression due to thromboembolic risks. |
| Teratogenic Risk | NORMINEST FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent exposure in large epidemiologic studies, but increased risk of cardiovascular and limb anomalies reported with higher doses. Second/third trimester: Androgenic effects causing clitoromegaly, labial fusion, and potential for impaired fetal growth. Postnatal: Possible long-term neurodevelopmental effects. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease (current or history)","Known or suspected breast carcinoma","Estrogen-dependent neoplasia (known or suspected)","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use","Hepatic adenoma or carcinoma (current or history)","Known or suspected pregnancy","Hypersensitivity to any component","Heavy smoking (≥15 cigarettes/day) in women over 35","Hemosiderosis or hemochromatosis (due to ferrous fumarate)"]
| Precautions | ["Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction.","Cigarette smoking increases cardiovascular risk; advise not to smoke.","Elevated blood pressure: monitor regularly.","Gallbladder disease: increased risk of cholelithiasis.","Liver tumors: benign and malignant hepatic adenomas reported.","Carbohydrate and lipid metabolism: monitor in diabetics and those with dyslipidemia.","Headache: may worsen or initiate migraine; discontinue if new headache pattern or persistent.","Bleeding irregularities: breakthrough bleeding and spotting are common; evaluate if persistent.","Ocular effects: retinal thrombosis may cause partial or complete loss of vision; discontinue if proptosis, diplopia, or papilledema.","Depression: discontinue if severe or persistent.","Iron overload: contraindicated in patients with hemosiderosis or hemochromatosis (due to ferrous fumarate)."] |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure, liver function, glucose tolerance, and signs of thrombophlebitis. Fetal monitoring via ultrasound for growth restriction and anomalies if exposure occurs during organogenesis. |
| Fertility Effects | Reversible suppression of ovulation; no permanent impact on fertility after discontinuation. Return to normal fertility typically occurs within 1-3 cycles. |